TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT04683250: Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities

Sponsor: Taiho Pharmaceutical Co., Ltd. · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 244 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$3,023,790

Rescue Site Savings

+$2,002,770

Unlock Full NCT04683250 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT04683250 Rescue Dossier →